Clinical Trial: A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy Participants

U.S., April 9 -- ClinicalTrials.gov registry received information related to the study (NCT06917508) titled 'A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy Participants' on April 01.

Brief Summary: The primary aim of this study is to assess the effect of EDP-323 on the pharmacokinetics and safety of midazolam, caffeine, and rosuvastatin in healthy adult participants.

Study Start Date: April, 2025

Study Type: INTERVENTIONAL

Condition: RSV Infection Drug Drug Interaction

Intervention: DRUG: EDP-323

Subjects will receive EDP-323 once daily on Days 5-15

DRUG: Midazolam

Subjects will receive midazolam once daily on Days 1 and 12

DRUG: Caffeine

Subjects will receive caffe...